Clinical trial NCT06122207: Effect of a Probiotic on the Female Genital Tract Microbiota of Participants With Fertility Disorders.
Official title: A Randomized, Double-blind, Placebo-controlled Study to Confirm the Positive Effect of Fertibiome® (Ligilactobacillus Salivarius PS11610) on the Female Genital Tract Microbiota of Couples or Women With Fertility Disorders.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Fertility Disorders
Lead sponsor: ProbiSearch SL
Sponsor class: INDUSTRY
First posted: 2023-11-08
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In the last decades, numerous publications have broken the old paradigm that considered the urogenital tracts as sterile, demonstrating that microorganisms present in the urogenital tract represent the 9% of the whole human microbiome. Healthy urogenital microbiome improves implantation rate and pregnancy outcomes, whereas 40% of dysbiosis prevalence is observed in women under assisted reproductive treatment (ART).

Infertility causes are associated with male, female, or combined failure. It has been shown that oral probiotic treatment, mainly with Lactobacillus, recovers a healthy vaginal microbiota without safety concerns.

An interventional, randomized, double-blind, placebo-controlled study will be conducted to confirm the positive effect of the commercial probiotic product Fertibiome® on the vaginal dysbiosis of couples or women with fertility disorders.

The duration of the study will be of 6 months approximately, including 6 months of product intake. In case of pregnancy during intervention, women will continue their participation until week 12 of gestation.

Participants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group. Women will take 1 capsule every 12 hours and men 1 per day. In case of women participating alone they will take 1 capsule every 12 hours. In case of pregnancy, only women will continue taking 1 capsule per day for the first 12 weeks.


Eligibility criteria: Inclusion Criteria:

* Couples or women with ages between 18 and 40 for woman and between 18 and 55 for man (in case of couple participation).
* Couples or women with fertility disorders.
* Couples or women undergoing IVF treatment or willing to start it.
* Signature of the Informed Consent.

Exclusion Criteria:

* Women, not participating in the study with a couple, who have not undergone at least 4 cycles of artificial insemination with donor's sperm (AID) or 1 cycle of IVF without achieving evolutionary pregnancy.
* Women with Body Mass Index (BMI) ≥ 30.
* Couples where the woman has not infertility diagnosis while the man has any of the following characteristics:

  * Azoospermia
  * Sperm motility (A + B) \< 25%.
  * Sperm morphology ≤ 2%.
  * Vas deferens obstruction.
* Couples or women with any of the following characteristics:

  * Chronic diseases that cause intestinal malabsortion.
  * Congenital or acquired immunodeficiency.
  * Current history or diagnosis of alcohol, tobacco, or drug abuse.
  * Uncertainty about the willingness or ability of participants to comply with the requirements of the protocol.
  * Under treatment with probiotics during the last week.

Primary outcomes:
measure: Percentage (%) of women with vaginal dysbiosis after 3 months of treatment.
timeFrame: After 3 months of intervention.
measure: Percentage (%) of women with vaginal dysbiosis after 6 months of treatment.
timeFrame: After 6 months of intervention.
Secondary outcomes:
measure: Number of vaginal dysbiosis criteria in case of pregnancy confirmation.
timeFrame: Up to 6 months.
measure: Percentage (%) of women with vaginal dysbiosis.
timeFrame: Before intervention.
measure: Number of dysbiosis criteria per woman.
timeFrame: Before intervention.
measure: Number of dysbiosis criteria per woman.
timeFrame: After 3 months of treatment pregnancy confirmation.
measure: Number of dysbiosis criteria per woman.
timeFrame: After 6 months of treatment or pregnancy confirmation.
measure: Percentage of Lactobacillus in vaginal microbiota.
timeFrame: Before intervention.
measure: Percentage of Lactobacillus in vaginal microbiota.
timeFrame: After 3 months of treatment or pregnancy confirmation.
measure: Percentage of Lactobacillus in vaginal microbiota.
timeFrame: After 6 months of treatment or pregnancy confirmation.
measure: Number of reproductive treatments during the study period.
timeFrame: After 6 months of treatment or pregnancy confirmation.
measure: Pregnancy rate.
timeFrame: After 6 months of treatment or pregnancy confirmation.
measure: Time elapsed from the beginning of the study, until the occurrence of pregnancy.
timeFrame: Up to 6 months.
measure: Spontaneous pregnancy rate, not associated to fertility treatment (IVF or AI).
timeFrame: Up to 6 months.
measure: Miscarriage rate in the first trimester of pregnancy.
timeFrame: Before 12 weeks of pregnancy.
measure: Number of oocytes extracted.
timeFrame: Before IVF cycle.
measure: Embryo Quality (A, B or C).
timeFrame: Before IVF cycle.
measure: Number of vaginal dysbiosis criteria at the time of embryo transfer per IVF cycle.
timeFrame: Before IVF cycle.
measure: Levels (pg/ml) of pro-inflammatory and anti-inflammatory markers in blood plasma of women.
timeFrame: Before intervention.
measure: Levels (pg/ml) of pro-inflammatory and anti-inflammatory markers in blood plasma of women.
timeFrame: After 6 months of treatment or pregnancy confirmation.
Other outcomes:
Locations:
city: Lisboa
country: Portugal
facility: Dr. Miguel Raimundo (Portugal)
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
state: Comunidad De Madrid
Study officials:
References: